Risperidone controlled release - DURECT/Zogenix

Drug Profile

Risperidone controlled release - DURECT/Zogenix

Alternative Names: Relday; Risperidone sustained release; SABER™ risperidone; ZX-003

Latest Information Update: 26 Oct 2015

Price : $50

At a glance

  • Originator DURECT Corporation
  • Developer DURECT Corporation; Zogenix
  • Class Antineoplastics; Antipsychotics; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Schizophrenia
  • Preclinical Bipolar disorders

Most Recent Events

  • 30 Sep 2015 Pharmacokinetics and adverse events data from a phase I trial in Schizophrenia released by Zogenix
  • 26 Mar 2015 Zogenix is considering partnering opportunities for controlled-release risperidone excluding USA. http://www.zogenix.com
  • 26 Mar 2015 Zogenix initiates enrolment in a phase Ib trial for Schizophrenia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top